

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

FLORFENIKEL 300 mg/ml solution for injection for cattle and pigs

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains

#### **Active substance:**

Florfenicol 300 mg

#### **Excipient:**

<b>Qualitative composition of excipients and other constituents</b>	<b>Quantitative composition if that information is essential for proper administration of the veterinary medicinal product</b>
N-methylpyrrolidone	200 mg
Glycerol formal	

Clear, light yellow to yellow solution.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Cattle, pigs

#### **3.2 Indications for use for each target species**

Cattle: Treatment of respiratory tract infections due to strains of *Mannheimia haemolytica*, *Pasteurella multocida* and *Histophilus somni* susceptible to florfenicol.

Pigs: Treatment of acute outbreaks of swine respiratory disease caused by strains of *Actinobacillus pleuropneumoniae* and *Pasteurella multocida* susceptible to florfenicol.

#### **3.3 Contraindications**

Do not use in adult bulls and boars intended for breeding purposes.

Do not use in piglets of less than 2 kg.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not administer intravenously.

### **3.4 Special warnings**

None.

### **3.5 Special precautions for use**

#### Special precautions for safe use in the target species:

Use of the veterinary medicinal product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.

Official national and regional antimicrobial policies should be taken into account when the product is used.

Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to florfenicol and may decrease the effectiveness of treatment with other amfenicols and other antimicrobials due to the potential for cross-resistance.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Care should be taken to avoid accidental self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Avoid direct contact with skin, mouth and eyes. If eye exposure occurs, flush eyes immediately with clean water. If skin exposure occurs, wash the affected area with clean water. If accidental ingestion occurs, rinse the mouth with plenty of water and seek medical advice immediately.

Wash hands after use.

People with known hypersensitivity to florfenicol should avoid contact with the veterinary medicinal product.

Do not smoke, eat or drink while handling this veterinary medicinal product.

Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have shown evidence of foetotoxic effects. Women of childbearing age, pregnant women or women suspected of being pregnant should use the veterinary medicinal product with serious caution to avoid accidental self-injection.

#### Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Cattle:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Reduced food intake <sup>1</sup> Loose stool <sup>1</sup> Injection site inflammation <sup>2</sup> ; Injection site lesion <sup>2</sup> Anaphylaxis
--	--

<sup>1</sup> Quick and complete recovery upon termination of treatment.

<sup>2</sup> May persist for 14 days after intramuscular administration.

Pigs

Common (1 to 10 animals / 100 animals treated):	Diarrhoea <sup>1</sup> ; Perianal inflammation <sup>1</sup> , Rectal oedema <sup>1</sup> ; Pyrexia <sup>2</sup> , Depression <sup>2,3</sup> ; Dyspnoea <sup>2,3</sup> ;
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Injection site swelling <sup>4</sup> , Injection site lesion <sup>5</sup> , Injection site inflammation <sup>5</sup> .

<sup>1</sup> Transient, can be observed for one week.

<sup>2</sup> For a week or more after administration of the second dose.

<sup>3</sup> Moderate.

<sup>4</sup> Transient, lasting up to 5 days.

<sup>5</sup> May be seen up to 28 days.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

#### Pregnancy, lactation and fertility:

The safety of the veterinary medicinal product has not been established in cattle and pigs during pregnancy and lactation or in animals intended for breeding.

Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have shown evidence of foetotoxic effects. Use only according to the benefit/risk assessment by the responsible veterinarian.

### **3.8 Interaction with other medicinal products and other forms of interaction**

No data available.

### **3.9 Administration routes and dosage**

Intramuscular use (i.m.)

To ensure a correct dosage body weight should be determined as accurately as possible. The stopper must be cleaned before removing each dose. Use a dry, sterile syringe and needle.

The vial cannot be broached more than 25 times.

Cattle: i.m. injection of 20 mg/kg BW (1ml/15kg) into the neck muscle twice 48 hours apart. The volume administered per injection site should not exceed 10 ml. Subsequent injections must be given at different sites.

Pigs: i.m. injection of 15 mg/kg BW (1 ml/20 kg) into the neck muscle, twice, 48 hour apart. The volume administered per injection site should not exceed 3 ml. Subsequent injections must be given at different sites.

It is recommended to treat animals in the early stages of disease and to evaluate the response to treatment within 48 hours after the second injection. If clinical signs of respiratory disease persist 48 hours after the last injection, treatment should be changed using another formulation or another antibiotic and continued until clinical signs have resolved.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

In swine after administration of 3 times the recommended dose or more a reduction in feeding, hydration and weight gain has been observed. After administration of 5 times the recommended dose or more vomiting has also been noted.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Cattle:

Meat and offal: 34 days

Milk: Not authorised for use in animals producing milk for human consumption.

Pigs:

Meat and offal: 18 days

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QJ01BA90**

### **4.2 Pharmacodynamics**

Florfenicol is a synthetic broad spectrum antibiotic effective against most Gram-positive and Gram-negative bacteria isolated from domestic animals. Florfenicol acts by inhibiting protein synthesis at the ribosomal level and is bacteriostatic.

However, bactericidal activity has been demonstrated in vitro against most common bacterial pathogens involved in respiratory disease: *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and *Actinobacillus pleuropneumonia*.

Acquired resistance to florfenicol is mediated by efflux pump resistance associated with a *flo* gene. Cross resistance with chloramphenicol can occur.

The following Minimal Inhibitory Concentrations (MIC) have been determined for florfenicol in European isolates collected from cattle and pigs with respiratory tract infections. For florfenicol in bovine and swine respiratory disease, CLSI breakpoints are: susceptible  $\leq 2$   $\mu\text{g/ml}$ , intermediate 4  $\mu\text{g/ml}$  and resistant  $\geq 8$   $\mu\text{g/ml}$ .

Species	Bacterial pathogen	MIC <sub>50</sub> (µg/ml)	MIC <sub>90</sub> (µg/ml)
Cattle	<i>Mannheimia haemolytica</i>	0.5 - 1	1
	<i>Pasteurella multocida</i>	0.5	0.5 - 1
	<i>Histophilus somni</i>	0.25	0.25
Pigs	<i>Actinobacillus pleuropneumonia</i>	0.25 – 0.5	0.5
	<i>Pasteurella multocida</i>	0.5	0.5

### 4.3 Pharmacokinetics

#### Cattle:

Intramuscular administration at the recommended dose of 20 mg/kg maintains efficacious blood levels in cattle for 48 hours. Maximum mean serum concentration (C<sub>max</sub>) of 4.02 µg/ml occurs at 7.0 hours (T<sub>max</sub>) after dosing.

The mean serum concentration 24 hours after dosing was 1.57 µg/ml. The terminal half-life was 15.1 hours.

#### Pigs:

After intramuscular administration of the recommended dose of 15 mg/kg, maximum serum concentration of 2.48 µg/ml is reached after 2.0 hours and the concentrations deplete with a terminal half-life of 14.9 hours.

Serum concentrations drop below 1 µg/ml, the MIC<sub>90</sub> for the target porcine pathogens, 12-24 hours following IM administration. Florfenicol concentrations achieved in lung tissue reflect plasma concentration, with a lung plasma concentration ratio of approximately 1. After administration to pigs by the intramuscular route, florfenicol is rapidly excreted, primarily in urine. The florfenicol is extensively metabolised.

### Environmental properties

The use of this veterinary medicinal product may pose a risk for terrestrial plants, cyanobacteria and groundwater organisms.

## 5. PHARMACEUTICAL PARTICULARS

### 5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life of the veterinary medicinal product packaged in colourless glass vials for sale: 3 years

Shelf life after first opening the immediate packaging: 28 days.

## **5.3 Special precautions for storage**

This veterinary medicinal product does not require any special temperature storage conditions. Keep the bottle in the outer carton in order to protect from light.

## **5.4 Nature and composition of immediate packaging**

Vial sizes: 100 and 250 ml

- Colourless Type II glass vials closed with bromobutyl rubber closures and an aluminium cap.
- Polypropylene vials closed with bromobutyl rubber closures and an aluminium cap.

Vials are individually packed in carton box.

Six, ten or twelve of these are grouped as clinical pack.

Not all pack sizes may be marketed.

## **5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

The veterinary medicinal product should not enter water courses as florfenicol may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Kela nv

## **7. MARKETING AUTHORISATION NUMBER**

Vm 06126/4001

## **8. DATE OF FIRST AUTHORISATION**

27 February 2012

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

May 2025

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT**

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

*Gavin Hall*

Approved: 26 August 2025